VBLT - ヴァスキュラ―・バイオジェニックス （Vascular Biogenics Ltd.） ヴァスキュラ―・バイオジェニックスVBLTのチャート
VBLTの企業情報
| symbol | VBLT |
|---|---|
| 会社名 | Vascular Biogenics Ltd. （ヴァスキュラ―・バイオジェニックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate VB-111(ofranergene obadenovec) is a gene-based biologic that it is developing for solid tumor indications with a program for recurrent glioblastoma (rGBM) a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program VB-201 is a Phase II-ready molecule. ヴァスキュラ―・バイオジェニックスはイスラエルでがんと炎症治療薬の発見、開発、商品化に焦点を置くバイオ医薬品企業。グリア芽腫(脳腫瘍)、卵巣がんの血管標的薬剤VB-111、また、酸化リン脂質を標的とした乾癬や潰瘍性結腸炎など慢性炎症の抗炎症剤VB-201の治験を行う。 Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL's lead oncology product candidate, ofranergene obadenovec (VB-111), is an investigational, first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VB-111 is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer. |
| 本社所在地 | 8 HaSatat St Modi'in 7178106 ISR |
| 代表者氏名 | Bennett M. Shapiro ベネット・M・シャピロ |
| 代表者役職名 | Chairman of the Board Independent Director |
| 電話番号 | +972 3-634-6450 |
| 設立年月日 | 36526 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | － |
| url | www.vblrx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/vblt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -11.14700 |
| 終値（lastsale） | 1.605 |
| 時価総額（marketcap） | 57548014.905 |
| 時価総額 | 時価総額（百万ドル） 51.27331 |
| 売上高 | 売上高（百万ドル） 14.20700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -6.26469 |
| 当期純利益 | 当期純利益（百万ドル） -11.46500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Vascular Biogenics Ltd revenues increased from $0K to $343K. Net loss increased 13% to $11.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development expenses net increase of 18% to $8.7M (expense) FINANCIAL INCOME decrease of 45% to $253K (income). |
VBLTのテクニカル分析
VBLTのニュース
How did Vascular Biogenics Ltd. (VBLT) fare last session? 2023/01/09 12:08:00 US Post News
The share price of Vascular Biogenics Ltd. (NASDAQ:VBLT) rose to $0.15 per share on Friday from $0.14. While Vascular Biogenics Ltd. has overperformed by 7.91%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VBLT fell by -91.63%, with highs and lows ranging from $2.20 to $0.10, […]
Vascular Biogenics Ltd. (NASDAQ:VBLT) Jumps 7.91%, But Additional Rally May Be Imminent 2023/01/07 12:00:00 Marketing Sentinel
In last trading session, Vascular Biogenics Ltd. (NASDAQ:VBLT) saw 2.19 million shares changing hands with its beta currently measuring 0.73. Company’s recent per share price level of $0.15 trading at $0.01 or 7.91% at ring of the bell on the day assigns it a market valuation of $10.48M. That closing price of VBLT’s stock is … Vascular Biogenics Ltd. (NASDAQ:VBLT) Jumps 7.91%, But Additional Rally May Be Imminent Read More »
What Does 2022 Hold For Vascular Biogenics Ltd. (NASDAQ:VBLT)? 2022/12/24 19:00:00 Stocks Register
Vascular Biogenics Ltd. (NASDAQ:VBLT) price on Friday, December 23, fall -3.48% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.11. A look at the stock’s price movement, the close in the last trading session was $0.12, moving within a range at $0.1101 and $0.1186. The beta value … What Does 2022 Hold For Vascular Biogenics Ltd. (NASDAQ:VBLT)? Read More »
Vascular Biogenics Ltd. (NASDAQ:VBLT) Has Reached A Distance Of 8.33% From Its Low, So Is It Poised For More Gains? 2022/12/16 15:30:00 Marketing Sentinel
In last trading session, Vascular Biogenics Ltd. (NASDAQ:VBLT) saw 2.06 million shares changing hands with its beta currently measuring 0.70. Company’s recent per share price level of $0.12 trading at -$0.01 or -4.77% at ring of the bell on the day assigns it a market valuation of $8.36M. That closing price of VBLT’s stock is … Vascular Biogenics Ltd. (NASDAQ:VBLT) Has Reached A Distance Of 8.33% From Its Low, So Is It Poised For More Gains? Read More »
Do investors need to be concerned about Vascular Biogenics Ltd. (VBLT)? 2022/12/12 16:40:00 US Post News
As of Friday, Vascular Biogenics Ltd.’s (NASDAQ:VBLT) stock closed at $0.13, up from $0.13 the previous day. While Vascular Biogenics Ltd. has overperformed by 2.47%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VBLT fell by -93.93%, with highs and lows ranging from $2.28 to $0.11, […]
Vascular Biogenics Ltd. (NASDAQ:VBLT) Currently -1853.85% Below Its 52-Week High, But There May Be A Surprise Downside 2022/10/15 17:00:00 Marketing Sentinel
In last trading session, Vascular Biogenics Ltd. (NASDAQ:VBLT) saw 0.47 million shares changing hands with its beta currently measuring 0.72. Company’s recent per share price level of $0.13 trading at -$0.01 or -4.52% at ring of the bell on the day assigns it a market valuation of $10.17M. That closing price of VBLT’s stock is … Vascular Biogenics Ltd. (NASDAQ:VBLT) Currently -1853.85% Below Its 52-Week High, But There May Be A Surprise Downside Read More »
Why Invest In Vascular Biogenics Ltd. (VBLT) Stock? 2022/10/12 20:00:00 Marketing Sentinel
Vascular Biogenics Ltd. (NASDAQ:VBLT) has a beta value of 0.72 and has seen 0.71 million shares traded in the recent trading session. The company, currently valued at $10.88M, closed the recent trade at $0.14 per share which meant 0.64% during that session. The VBLT stock price is -1714.29% off its 52-week high price of $2.54 … Why Invest In Vascular Biogenics Ltd. (VBLT) Stock? Read More »
Vascular Biogenics Ltd. (VBLT) can excel with these strategies 2022/09/06 13:40:00 US Post News
The share price of Vascular Biogenics Ltd. (NASDAQ:VBLT) fell to $0.21 per share on Friday from $0.21. While Vascular Biogenics Ltd. has underperformed by -2.58%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VBLT fell by -91.65%, with highs and lows ranging from $2.54 to $0.20, […]
Analysts Predict Vascular Biogenics Ltd. (NASDAQ:VBLT) To Reach $5.00 In 12 Months 2022/09/01 14:30:00 Marketing Sentinel
In last trading session, Vascular Biogenics Ltd. (NASDAQ:VBLT) saw 3.53 million shares changing hands with its beta currently measuring 0.59. Company’s recent per share price level of $0.23 trading at $0.01 or 0.85% at ring of the bell on the day assigns it a market valuation of $16.07M. That closing price of VBLT’s stock is … Analysts Predict Vascular Biogenics Ltd. (NASDAQ:VBLT) To Reach $5.00 In 12 Months Read More »
Vascular Biogenics Ltd.’s (NASDAQ:VBLT) Stock Is Up 5.45%, But Is It Capable Of A Rally? 2022/08/30 15:30:00 Stocks Register
Vascular Biogenics Ltd. (NASDAQ:VBLT) traded at $0.23 at close of the session on Monday, 08/29/22, made an upward move of 5.45% on its previous day’s price. Looking at the stock we see that its previous close was $0.22 and the beta (5Y monthly) reads 1.09 with the day’s price range being $0.2114 – $0.2418. In … Vascular Biogenics Ltd.’s (NASDAQ:VBLT) Stock Is Up 5.45%, But Is It Capable Of A Rally? Read More »
Boom Or Bust: What Does The Future Hold For Vascular Biogenics Ltd. (NASDAQ: VBLT) Stock? 2022/06/18 12:30:00 Marketing Sentinel
Vascular Biogenics Ltd. (NASDAQ:VBLT)’s traded shares stood at 0.12 million during the last session, with the company’s beta value hitting 1.09. At the close of trading, the stock’s price was $1.36, to imply an increase of 4.62% or $0.06 in intraday trading. The VBLT share’s 52-week high remains $2.59, putting it -90.44% down since that … Boom Or Bust: What Does The Future Hold For Vascular Biogenics Ltd. (NASDAQ: VBLT) Stock? Read More »
VBL Therapeutics to Participate in the Jefferies Healthcare Conference 2022/05/31 12:00:00 GlobeNewswire
TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will present a corporate overview and participate in investor meetings at the upcoming Jefferies Healthcare Conference being held in New York on June 8 – 10, 2022.
Trading - Vascular Biogenics Ltd. Short Interest Update 2022/05/29 11:07:08 Business Mag
Vascular Biogenics Ltd. was the target of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 452,400 shares, a drop of 34.2%…
Equities Analysts Set Expectations for Vascular Biogenics Ltd.’s Q2 2022 Earnings (NASDAQ:VBLT) 2022/05/20 13:32:51 ForexTV
Stock analysts at Oppenheimer reduced their Q2 2022 EPS estimates for shares of Vascular Biogenics in a research note issued to investors on Tuesday, May 17th. Oppenheimer analyst K. Degeeter now … Read Full Story at source (may require registration) The post Equities Analysts Set Expectations for Vascular Biogenics Ltd.’s Q2 2022 Earnings (NASDAQ:VBLT) appeared first on ForexTV .
Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q1 2022 Results - Earnings Call Transcript 2022/05/17 17:10:07 Seeking Alpha
Vascular Biogenics Ltd. (NASDAQ:NASDAQ:VBLT) Q1 2022 Earnings Conference Call May 17, 2022, 08:30 AM ET Company Participants Dan Ferry - LifeSci Advisors, IR Dror Harats - CEO Sam…